PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

PharmaTher Holdings announced that the U.S. FDA has accepted IND application to proceed with a Phase 2 clinical trial evaluating ketamine in the treatment of ALS

Related Keywords

United States ,American ,Richard Barohn ,Lou Gehrig ,University Of Kansas ,Human Services ,Drug Administration ,University Of Missouri ,Health Affairs ,Pharmather Holdings Ltd ,Nextgen Precision Health ,Department Of Health ,Mu Health Care ,Association Of American Physicians ,Amyotrophic Lateral Sclerosis ,Primary Investigator ,President Biden ,Critical Therapies ,Rating Scale ,Executive Director ,Executive Vice Chancellor ,